{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T12:19:03Z","timestamp":1788437943129,"version":"build-2803163510"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>Abstract:<\/jats:title>\n                  <jats:p>Obesity is now recognized as a chronic, multifactorial, and progressive disease as opposed to mere excess of body weight. It significantly increases the risk of type 2 diabetes, cardiovascular disease, metabolic-associated fatty liver disease, and mental health disorders. 2022 data reveal that nearly 3 billion individuals worldwide were living with either obesity or overweight. Pharmacological therapy has evolved remarkably. Earlier medications targeted primarily the brain\u2019s monoaminergic pathways but they were withdrawn due to safety concerns. Currently, six medications (Orlistat, Phentermine\/Topiramate, Naltrexone\/Bupropion, Liraglutide, Semaglutide, and Tirzepatide) are approved by the U.S. Food and Drug Administration for long-term obesity management and among these, glucagon-like peptide receptor agonists have revolutionized the therapy. The emerging pipeline is even more promising. It has new dual and triple combinations such as CagriSema, Survodutide, and Retatrutide for better efficacy and metabolic outcomes, as well as long-acting and oral formulations, which will improve adherence and accessibility. India released its new obesity guideline in January 2025, emphasizing on early pharmacotherapy initiation and the adoption of stage-based obesity classification. Together, these developments signify a transformative era in obesity care where pharmacotherapy is a powerful and evidence-based tool that, in many cases, approaches the efficacy and metabolic benefits traditionally associated with bariatric surgeries.<\/jats:p>","DOI":"10.4103\/ijp.ijp_37_26","type":"journal-article","created":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T13:00:06Z","timestamp":1788354006000},"page":"505-512","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Pharmacological management of obesity: Current landscape and emerging therapies"],"prefix":"10.4103","volume":"58","author":[{"given":"Shubham","family":"Atal","sequence":"first","affiliation":[{"name":"Department of Pharmacology, All India Institute of Medical Sciences, Bhopal, Madhya Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chirag","family":"Agrawal","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, All India Institute of Medical Sciences, Bhopal, Madhya Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul","family":"Gupta","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, All India Institute of Medical Sciences, Bhopal, Madhya Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Balakrishnan","family":"Sadasivam","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, All India Institute of Medical Sciences, Bhopal, Madhya Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,9,2]]},"reference":[{"key":"R2-20260903","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S2213-8587(24)00316-4","article-title":"Definition and diagnostic criteria of clinical obesity","volume":"13","author":"Rubino","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"key":"R3-20260903","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1159\/000497124","article-title":"The ABCD of obesity: An EASO position statement on a diagnostic term with clinical and scientific implications","volume":"12","author":"Fr\u00fchbeck","year":"2019","journal-title":"Obes Facts"},{"key":"R4-20260903","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1186\/s12916-016-0735-y","article-title":"Post-marketing withdrawal of anti-obesity medicinal products because of adverse drug reactions: A systematic review","volume":"14","author":"Onakpoya","year":"2016","journal-title":"BMC Med"},{"key":"R12-20260903","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0140-6736(23)01185-6","article-title":"Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"402","author":"Knop","year":"2023","journal-title":"Lancet"},{"key":"R13-20260903","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1056\/NEJMoa2500969","article-title":"Oral semaglutide at a dose of 25 mg in adults with overweight or obesity","volume":"393","author":"Wharton","year":"2025","journal-title":"N Engl J Med"},{"key":"R18-20260903","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1042\/bj0010028","article-title":"On the treatment of diabetus mellitus by acid extract of duodenal mucous membrane","volume":"1","author":"Moore","year":"1906","journal-title":"Biochem J"},{"key":"R19-20260903","doi-asserted-by":"crossref","first-page":"260","DOI":"10.3389\/fendo.2019.00260","article-title":"From the incretin concept and the discovery of GLP-1 to today\u2019s diabetes therapy","volume":"10","author":"Holst","year":"2019","journal-title":"Front Endocrinol (Lausanne)"},{"key":"R20-20260903","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/S0140-6736(64)90011-X","article-title":"New interpretation of oral glucose tolerance","volume":"2","author":"Mcintyre","year":"1964","journal-title":"Lancet"},{"key":"R21-20260903","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/BF00281990","article-title":"New developments in the incretin concept","volume":"28","author":"Creutzfeldt","year":"1985","journal-title":"Diabetologia"},{"key":"R22-20260903","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1210\/jcem-37-5-826","article-title":"Stimulation of insulin secretion by gastric inhibitory polypeptide in man","volume":"37","author":"Dupre","year":"1973","journal-title":"J Clin Endocrinol Metab"},{"key":"R23-20260903","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1038\/304368a0","article-title":"Exon duplication and divergence in the human preproglucagon gene","volume":"304","author":"Bell","year":"1983","journal-title":"Nature"},{"key":"R24-20260903","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.amjmed.2025.01.021","article-title":"Mechanisms of GLP-1 receptor agonist-induced weight loss: A review of central and peripheral pathways in appetite and energy regulation","volume":"138","author":"Moiz","year":"2025","journal-title":"Am J Med"},{"key":"R25-20260903","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1038\/s42255-025-01294-x","article-title":"GIPR agonism and antagonism decrease body weight and food intake via different mechanisms in male mice","volume":"7","author":"Gutgesell","year":"2025","journal-title":"Nat Metab"},{"key":"R26-20260903","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1056\/NEJMoa2511774","article-title":"Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment","volume":"393","author":"Wharton","year":"2025","journal-title":"N Engl J Med"},{"key":"R27-20260903","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S2213-8587(25)00226-8","article-title":"Once-weekly semaglutide 7\u00b72 mg in adults with obesity (STEP UP): A randomised, controlled, phase 3b trial","volume":"13","author":"Wharton","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"key":"R28-20260903","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S2213-8587(23)00356-X","article-title":"Glucagon and GLP-1 receptor dual agonist survodutide for obesity: A randomised, double-blind, placebo-controlled, dose-finding phase 2 trial","volume":"12","author":"le Roux","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"key":"R29-20260903","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1056\/NEJMoa2411528","article-title":"Once-weekly mazdutide in Chinese adults with obesity or overweight","volume":"392","author":"Ji","year":"2025","journal-title":"N Engl J Med"},{"key":"R30-20260903","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1056\/NEJMoa2504214","article-title":"Once-monthly maridebart cafraglutide for the treatment of obesity \u2013 A phase 2 Trial","volume":"393","author":"Jastreboff","year":"2025","journal-title":"N Engl J Med"},{"key":"R31-20260903","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1056\/NEJMoa2502081","article-title":"Coadministered cagrilintide and semaglutide in adults with overweight or obesity","volume":"393","author":"Garvey","year":"2025","journal-title":"N Engl J Med"},{"key":"R33-20260903","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa2301972","article-title":"Triple-hormone-receptor agonist retatrutide for obesity \u2013 A phase 2 trial","volume":"389","author":"Jastreboff","year":"2023","journal-title":"N Engl J Med"},{"key":"R34-20260903","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/S2213-8587(25)00216-5","article-title":"Efficacy and safety of monlunabant in adults with obesity and metabolic syndrome: A double-blind, randomised, placebo-controlled, phase 2a trial","volume":"13","author":"Knop","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"key":"R35-20260903","doi-asserted-by":"crossref","first-page":"e2033457","DOI":"10.1001\/jamanetworkopen.2020.33457","article-title":"Effect of bimagrumab versus placebo on body fat mass among adults with type 2 diabetes and obesity: A phase 2 randomized clinical trial","volume":"4","author":"Heymsfield","year":"2021","journal-title":"JAMA Netw Open"},{"key":"R36-20260903","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1056\/NEJMoa2407379","article-title":"Liraglutide for children 6 to <12 years of age with obesity-A randomized trial","volume":"392","author":"Fox","year":"2025","journal-title":"N Engl J Med"},{"key":"R38-20260903","doi-asserted-by":"crossref","first-page":"102989","DOI":"10.1016\/j.dsx.2024.102989","article-title":"Revised definition of obesity in Asian Indians living in India","volume":"19","author":"Misra","year":"2025","journal-title":"Diabetes Metab Syndr"}],"container-title":["Indian Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijp.ijp_37_26","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T12:03:58Z","timestamp":1788437038000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijp.ijp_37_26"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":24,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.4103\/ijp.ijp_37_26","relation":{},"ISSN":["0253-7613","1998-3751"],"issn-type":[{"value":"0253-7613","type":"print"},{"value":"1998-3751","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"2026-01-08","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-05","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}